🎉 M&A multiples are live!
Check it out!

Tempest Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Tempest Therapeutics and similar public comparables like Julphar, Vivoryon Therapeutics, and Benevolent AI.

Tempest Therapeutics Overview

About Tempest Therapeutics

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.


Founded

2011

HQ

United States of America
Employees

25

Website

tempesttx.com

Financials

LTM Revenue n/a

LTM EBITDA -$52.5M

EV

$9.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Tempest Therapeutics Financials

Tempest Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$52.5M.

In the most recent fiscal year, Tempest Therapeutics achieved revenue of n/a and an EBITDA of -$40.1M.

Tempest Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Tempest Therapeutics valuation multiples based on analyst estimates

Tempest Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$27.7M -$40.1M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$35.7M -$29.5M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Tempest Therapeutics Stock Performance

As of April 15, 2025, Tempest Therapeutics's stock price is $7.

Tempest Therapeutics has current market cap of $24.5M, and EV of $9.6M.

See Tempest Therapeutics trading valuation data

Tempest Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$9.6M $24.5M XXX XXX XXX XXX $-18.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Tempest Therapeutics Valuation Multiples

As of April 15, 2025, Tempest Therapeutics has market cap of $24.5M and EV of $9.6M.

Tempest Therapeutics's trades at n/a LTM EV/Revenue multiple, and -0.2x LTM EBITDA.

Analysts estimate Tempest Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Tempest Therapeutics and 10K+ public comps

Tempest Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $9.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.2x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Tempest Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Tempest Therapeutics Valuation Multiples

Tempest Therapeutics's NTM/LTM revenue growth is n/a

Tempest Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.7M for the same period.

Over next 12 months, Tempest Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Tempest Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Tempest Therapeutics and other 10K+ public comps

Tempest Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 45% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Tempest Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Tempest Therapeutics M&A and Investment Activity

Tempest Therapeutics acquired  XXX companies to date.

Last acquisition by Tempest Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Tempest Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Tempest Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Tempest Therapeutics

When was Tempest Therapeutics founded? Tempest Therapeutics was founded in 2011.
Where is Tempest Therapeutics headquartered? Tempest Therapeutics is headquartered in United States of America.
How many employees does Tempest Therapeutics have? As of today, Tempest Therapeutics has 25 employees.
Who is the CEO of Tempest Therapeutics? Tempest Therapeutics's CEO is Mr. Stephen R. Brady.
Is Tempest Therapeutics publicy listed? Yes, Tempest Therapeutics is a public company listed on NAS.
What is the stock symbol of Tempest Therapeutics? Tempest Therapeutics trades under TPST ticker.
When did Tempest Therapeutics go public? Tempest Therapeutics went public in 2021.
Who are competitors of Tempest Therapeutics? Similar companies to Tempest Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Tempest Therapeutics? Tempest Therapeutics's current market cap is $24.5M
What is the current EBITDA of Tempest Therapeutics? Tempest Therapeutics's last 12-month EBITDA is -$52.5M.
What is the current EV/EBITDA multiple of Tempest Therapeutics? Current EBITDA multiple of Tempest Therapeutics is -0.2x.
Is Tempest Therapeutics profitable? Yes, Tempest Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.